Endra Life Sciences portfolio increases to 70 issued patents

The following three patents were issued: U.S. Patent No. 11806113, titled “Thermoacoustic Probe,” relates to a novel thermoacoustic probe with an optical transducer and an integrated wedge. This builds upon ENDRA’s U.S. Patent No. 11730374, which defines and protects ENDRA’s integrated wedge technology. Chinese Patent No. ZL 2021800299011 titled “Thermoacoustic Transducer with Integrated Switch,” relates to a novel system for reducing false signals in thermoacoustic imaging. ENDRA expects the ‘011 patent to be effective for all thermoacoustic imaging applications. The Chinese ‘011 patent is related to its parent patent, U.S. Patent No. 11172829. Chinese Patent No. ZL 2022800094336 , titled “Acoustically Isolated Thermoacoustic Imaging Probe and Process of Manufacture,” protects ENDRA’s proprietary manufacturing process to acoustically isolate the radiofrequency element from the transducer element. The Chinese ‘336 patent is related to its parent patent, U.S. Patent No. US10996163. “Our IP portfolio has reached a new milestone of 70 issued patents globally. We believe this is a remarkable achievement for a company of our size and a testament to the innovation of ENDRA,” stated ENDRA’s Chairman and Chief Executive Officer Francois Michelon. “These newly issued patents protect and further differentiate ENDRA’s thermoacoustic systems in areas of high unmet clinical need, such as the early detection of steatotic liver disease.”